profit from every $100 of sales.
$0$100
Calidi Biotherapeutics
$0.62-5.08% today
-97.3% in 1 year
1-year low $0.621-year high $23.10
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Calidi Biotherapeutics sold, what it kept, and what it did with the cash.
Sales went from $45,000 in 2022 to $0 in 2025, with -$19.9 million of profit last year.
SalesProfit
Calidi Biotherapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Calidi Biotherapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Calidi Biotherapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| 0 | 0 | – | – | |
| -23 | -26 | -22 | -20 | |
| -25 | -27 | -20 | -18 | |
| -25 | -29 | -22 | -20 | |
| -84.98 | -207.96 | -35.70 | -5.95 | |
| 68.9% | – | – | – | |
| -51,395.6% | – | – | – | |
| -56,504.4% | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 3 | 10 | 14 | 9 |
| Cash | 0 | 2 | 10 | 6 |
| Total debt | 6 | 7 | 7 | 3 |
| Total liabilities | 53 | 18 | 12 | 5 |
| -50 | -8 | 2 | 4 | |
| 0 | 0 | 1 | 4 | |
| – | – | -196.0% | -247.9% | |
| 50.4% | 354.8% | -1,443.5% | -529.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -13 | -27 | -20 | -21 | |
| 0 | 1 | 0 | 0 | |
| -14 | -28 | -20 | -21 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 6 | 5 | 3 | 2 |
Valuation
- –
- –
- –
- 0.4×
- 50.8×
- –
- –
- -596.7%
- -1,112.1%
- 0.0%
Profitability
- 68.9%
- -51,395.6%
- -56,504.4%
- 0.0%
- -314.4%
- 494.3%
- -410.8%
- -224.7%
- -411.2%
- –
Growth
- –
- –
- −8.6%
- –
- +106.1%
Financial health
- –
- 0.52
- 22.2%
- -97.8×
- 1.59
- 1.59
- 0.00
What analysts expect
- Average price target
- $5.50
- Range
- $2.00 – $9.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.43 | – | – |
| Mar 27, 2026 | -0.57 | -1.56 | +63.5% |
| Nov 13, 2025 | -2.21 | -1.68 | −31.5% |
| Aug 8, 2025 | -1.99 | -1.92 | −3.6% |
| May 14, 2025 | -2.16 | -0.15 | −1,340.0% |
| Apr 4, 2025 | -0.51 | -0.37 | −37.8% |
| Nov 12, 2024 | -7.80 | -0.85 | −817.6% |
| Aug 13, 2024 | -16.81 | -1.43 | −1,075.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/7Passes 4 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
62Pass
Benjamin Graham
65Pass
Philip Fisher
37No pass
Peter Lynch
21No pass
Joel Greenblatt
2No pass
Charlie Munger
75Pass
Terry Smith
74Pass
Questions about Calidi Biotherapeutics
Is Calidi Biotherapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 4 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Calidi Biotherapeutics AI analysis
What does Calidi Biotherapeutics do?
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It is in Biotechnology.
Does Calidi Biotherapeutics pay a dividend?
No. Calidi Biotherapeutics does not pay a dividend at the moment.
Is Calidi Biotherapeutics stock halal?
No. Calidi Biotherapeutics does not pass our halal screen: its debt is 112% of its market value, at or above the 33% limit. How we check
How has Calidi Biotherapeutics stock done over the past year?
Down 97.3% over the past twelve months, to $0.62. It traded between $0.62 and $23.10 and is 97.3% below its high.
Who are Calidi Biotherapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Calidi Biotherapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.